Critical success factors for tomorrow’s cellular immunotherapies

Cell & Gene Therapy Insights 2021; 7(10), 1439–1445


Published: 17 November 2021
Peter Emtage

Peter Emtage is a Venture Partner with Versant Ventures. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design Labs Inc., which was acquired by Gilead, and Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at MedImmune. He has over 25 years of drug development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation.